tanruprubart

Tanruprubart is a humanized recombinant monoclonal antibody of the IgG4-kappa subtype that specifically targets complement component C1q, the initiating molecule of the classical complement cascade. By binding to and inhibiting C1q, tanruprubart blocks activation of the classical pathway of complement-mediated inflammation and tissue damage. This mechanism is being investigated for its potential to treat diseases driven by aberrant or excessive activation of the classical complement pathway, including Guillain-Barre syndrome (GBS), Huntington's disease, amyotrophic lateral sclerosis (ALS), and autoimmune hemolytic anemia. Tanruprubart has received orphan drug designation for GBS and Huntington's disease[6][8][10].

Other names

tanruprubart immunoglobulin G4-kappaanti-[Homo sapiens C1q (complement C1q)]ANX 005ANX005ANX-005